Mulay James 4
4 · CG Oncology, Inc. · Filed Oct 10, 2025
Insider Transaction Report
Form 4
Mulay James
Director
Transactions
- Exercise/Conversion
Common Stock
2025-10-09$3.72/sh+5,903$21,959→ 5,903 total - Sale
Common Stock
2025-10-09$43.99/sh−5,903$259,673→ 0 total - Exercise/Conversion
Director Stock Option (right to buy)
2025-10-09−5,903→ 1,962 totalExercise: $3.72Exp: 2033-06-13→ Common Stock (5,903 underlying)
Footnotes (2)
- [F1]The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.
- [F2]The stock option vests in 36 substantially equal monthly installments beginning on July 14, 2023.